Recent

% | $
Quotes you view appear here for quick access.

ONYX Pharmaceuticals, AŞ Message Board

  • johnpapas893 johnpapas893 Jul 7, 2013 2:11 PM Flag

    Comparators

    In 2008, Takeda paid $8.8 billion for Millenium Pharmaceuticals--basically for Velcade. It is true that the MM space was less crowded then and Velcade had received front-line approval. Still, by comparison Onyx's oncology portfolio is much more impressive: Kyprolis (with substantially less peripheral neuropath and very likely superior efficacy relative to Velcade), Nexavar, Stivarga (substantial royalties), Oprozomib, Palbociclib (8% roylaties but a likely blockbuster).

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • John, ONXX now trades at 9.9B valuation, 15% more than AMGN offer already. I expect offer at $140-$145 not more. And I'm not convinced that Dr Coles will sell at that price so we could drop back to $100, at least temporarily. I also think that we'll know this way or another in the next 2 weeks...